Eisai Inc:企業の戦略的SWOT分析

GlobalDataが発行した調査報告書(SWOT20MY2103)
◆英語タイトル:Eisai Inc - Strategic SWOT Analysis Review
◆商品コード:SWOT20MY2103
◆発行会社(リサーチ会社):GlobalData
◆発行日:2019年12月
◆ページ数:36
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥39,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Eisai Inc – Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Eisai Inc (Eisai) is a healthcare company, which focuses on the discovery, development and marketing of pharmaceutical products. The company’s major products include Aricept for Alzheimer’s treatment, Aciphex for acid reflux, Akynzeo for nausea and vomiting dring the course of cancer chemotherapy, Aloxi anti-nausea medication injection, Banzel for adjunctive treatment and Panretin for the treatment of skin lesions in AIDS-related Kaposi’s sarcoma. The company’s research and development activities focus on therapeutic areas such as neuroscience; cancer, antibody-based programs; vascular, inflammatory and immunological reaction. Eisai established partnerships and collaborations with global companies such as Pfizer Inc., Janssen Pharmaceutica Inc., and Elan Pharma International Limited and Elan Pharmaceutical Inc for the development and distribution of drugs. The company is a subsidiary of Eisai Co., Ltd. and is headquartered in New Jersey, the US.

Eisai Inc Key Recent Developments

Dec 05,2019: Beneath the Breast Campaign from Eisai and METAvivor supports relationship challenges commonly faced by people living with Metastatic Breast Cancer and their loved ones
Aug 26,2019: Priya Chaturvedi, Ph.D., appointed Vice President of Global Clinical Quality Assurance at Eisai
Jul 09,2019: Eisai commemorates opening of center for genetics guided dementia discovery in Cambridge, Massachusetts
Jun 04,2019: Patrick Coyle appointed Vice President and Chief Financial Officer of Eisai
May 29,2019: Adriana Herrera appointed senior vice president, Americas commercial oncology at Eisai

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Eisai Inc – Key Facts
Eisai Inc – Key Employees
Eisai Inc – Key Employee Biographies
Eisai Inc – Major Products and Services
Eisai Inc – History
Eisai Inc – Company Statement
Eisai Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Eisai Inc – Business Description
Eisai Inc – Corporate Strategy
Eisai Inc – SWOT Analysis
SWOT Analysis – Overview
Eisai Inc – Strengths
Eisai Inc – Weaknesses
Eisai Inc – Opportunities
Eisai Inc – Threats
Eisai Inc – Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Eisai Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Eisai Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Eisai Inc, Recent Deals Summary
Section 4 – Company’s Recent Developments
Dec 05, 2019: Beneath the Breast Campaign from Eisai and METAvivor supports relationship challenges commonly faced by people living with Metastatic Breast Cancer and their loved ones
Aug 26, 2019: Priya Chaturvedi, Ph.D., appointed Vice President of Global Clinical Quality Assurance at Eisai
Jul 09, 2019: Eisai commemorates opening of center for genetics guided dementia discovery in Cambridge, Massachusetts
Jun 04, 2019: Patrick Coyle appointed Vice President and Chief Financial Officer of Eisai
May 29, 2019: Adriana Herrera appointed senior vice president, Americas commercial oncology at Eisai
May 02, 2019: Eisai deepens its commitment to Alzheimer’s disease with key executive appointments
May 01, 2019: Eisai acquires rights to lemborexant from Purdue Pharma
Mar 13, 2019: TRIA to design new dementia discovery center for Eisai
Sep 06, 2018: Oncodesign furthers its cooperation with Eisai, started 12 years ago
Aug 31, 2018: XingImaging announces alzheimer’s disease PET imaging in Mainland China
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

List of Tables
Eisai Inc, Key Facts
Eisai Inc, Key Employees
Eisai Inc, Key Employee Biographies
Eisai Inc, Major Products and Services
Eisai Inc, History
Eisai Inc, Other Locations
Eisai Inc, Subsidiaries
Eisai Inc, Key Competitors
Eisai Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Eisai Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Eisai Inc, Recent Deals Summary

List of Figures
Eisai Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Eisai Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Eisai Inc:企業の戦略的SWOT分析(Eisai Inc - Strategic SWOT Analysis Review)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆